Prostate Specific Antigen Changes as Related to the Initial Prostate Specific Antigen: Data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
- 1 April 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 175 (4), 1286-1290
- https://doi.org/10.1016/s0022-5347(05)00706-8
Abstract
Conclusions For men choosing PSA screening, screening every 5 years for baseline PSA less than 1 ng/ml and every 2 years for PSA 1 to 2 ng/ml could result in a 50% reduction in PSA tests and in less than 1.5% of men missing earlier positive screens, but with an unknown effect on prostate cancer mortality.Keywords
This publication has 17 references indexed in Scilit:
- Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized TrialJNCI Journal of the National Cancer Institute, 2005
- American Cancer Society Guidelines for the Early Detection of Cancer, 2003CA: A Cancer Journal for Clinicians, 2003
- Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2002
- Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing TrendsJNCI Journal of the National Cancer Institute, 2001
- Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Comparing several score tests for interval censored dataStatistics in Medicine, 1999
- Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancerPublished by American Medical Association (AMA) ,1997
- Prospective Longitudinal Evaluation of Men With Initial Prostate Specific Antigen Levels of 4.0 Ng./Ml. or LessJournal of Urology, 1997
- Longitudinal screening for prostate cancer with prostate-specific antigenPublished by American Medical Association (AMA) ,1996
- Age- and race-specific reference ranges for prostate-specific antigen from a large community-based studyUrology, 1996